ViVeM Center

Formely know as "CPV core facility", ViVeM center offers an integrated service for the development of a "drug candidate" viral vector from proof of concept to the production of characterized pre-clinical batches for regulatory toxicology studies. Usually our production service can provide viral vectors derived from adenovirus-associated viruses (AAV) serotypes 1 to rh10, novel variants and research-grade adenovirus.

An R&D team develops innovative compliant-GMP (Good Manufacturing Practice) production and purification processes, including a quality control team that develops specific analytical methods for the vectors produced. The developed processes are directly transfered within a pharmaceutical establishment for the production and characterization of clinical grade vector batches.

The pre-clinical platform also provides technical, scientific and regulatory advices for users.

Photo Credit : University of Nantes

To implement these activities, the platform relies on specific know-how :

• developing tools and processes for the production, purification and characterization of clinical grade viral vectors
• produce pre-clinical grade viral vectors (research grade)
• advising on the choice of vectors (viral vector design) and their use

The vectors produced within the platform find solid applications in several fields:

• medicine and human health
• gene therapy
• medical research
• clinical research and trials
• biology and biotechnologies
• genetic engineering
• cell and molecular biology

• For cell culture and quality control :
  • 15 Biosafety cabinet-class II
  • 21 CO2 incubators
  • 7 freezers -80°C
  • 3 ultracentrifuges
  • 1 quantitative PCR
  • 1 DNA extraction robot Starlet Hamilton
  • Spectrophotometer, fluorometer, luminometer
  • 1 VICELL cell counting system
  • 1 fluorescence microscope
• Equipment specific to the activity :
  • 3 Biostat bioreactors
  • BSL3 and double input autoclave
  • 5 liquid chromatography chains including 1 Akta Ready
  • 2 TFF KR2i systems